Clinical Pharmacist Leadership in Precision Medicine & PGx

Clinical Pharmacist Role in Precision Medicine

From Pharmacogenomics to Targeted Drug Delivery

Dr. [Name]

Clinical Pharmacist & Precision Medicine Specialist

Genotype → Phenotype → Drug Exposure → Clinical Outcome → Decision → Monitoring

WHY WE ARE HERE

40–60%

of patients do NOT respond to their prescribed drug

15–25%

experience serious adverse drug reactions

WHO | FDA | PharmGKB

The Root Cause

Genetic variation → altered enzyme activity → wrong drug exposure

No PGx testing → empiric dosing → preventable harm

Pharmacist excluded from decision → missed intervention

Genotype → Phenotype → Drug Exposure → Clinical Outcome → Decision → Monitoring

Open with silence. Show stat. Ask: 'How many of your patients are in this 40%?' Pause 10 seconds. Let it land.

Precision Medicine: A Mechanistic Definition

GENOMIC DATA

DNA Sequences & Variants

PHENOTYPE PREDICTION

Enzyme / Target Activity

DRUG SELECTION

Avoidance & Alternatives

DOSE OPTIMIZATION

PK/PD Modifiers

OUTCOME MONITORING

Efficacy & Toxicity Metrics

It's NOT personalized medicine

That's marketing language

It IS variant-driven decision science

Genomic variants predict drug metabolism phenotype

Clinical Pharmacist = The Decision Architect

Translates genomic data into actionable drug therapy decisions

Genotype → Phenotype → Drug Exposure → Clinical Outcome → Decision → Monitoring

Your Clinical Compass

Every case in this session follows this framework

GENOTYPE

Variant detected (e.g., CYP2C19 *2/*2)

PHENOTYPE

Poor Metabolizer predicted

DRUG EXPOSURE

AUC ↑, Clearance ↓

CLINICAL OUTCOME

Toxicity or Therapeutic Failure

DECISION

Pharmacist Intervenes

MONITORING

TDM + Biomarker Tracking

CPIC Level A Evidence | PharmGKB | FDA PGx Biomarker Table

CYP450 Enzyme Variability — The Pharmacogenomic Engine

CYP450: The Drug Metabolism Switchboard

CYP2C19

Clopidogrel, PPIs, Citalopram

13+ allelic variants

CYP2D6

Codeine, Tamoxifen, Antidepressants

100+ allelic variants

CYP2C9

Warfarin, NSAIDs, Phenytoin

IM/PM variants alter bleeding risk

CYP3A4/5

~50% of all drugs

Ethnic variability critical

Pharmacogenomic Mechanism Framework

What Genotype Does to Your PK Parameters

Precision Medicine Symposium

Dr. [Name]

Clinical Pharmacist & Precision Medicine Specialist

Precision Medicine Core Principle: Proactive PK Intervention

CLINICAL CASE 1 — CARDIOLOGY: The Clopidogrel Paradox

CASE 01

52-year-old male. Post-PCI (drug-eluting stent).

On standard Clopidogrel 75mg/day.

Day 30: Stent thrombosis. Readmitted.

Patient was compliant.

Genetic resistance.

GENOTYPE

CYP2C19 *2/*2

Loss-of-function homozygous

Poor Metabolizer

PHENOTYPE

Hepatic CYP2C19 absent

Clopidogrel NOT converted to active thiol metabolite

DRUG EXPOSURE

Active metabolite AUC ↓ 80%

Platelet inhibition: <20% vs target 40-60%

CLINICAL OUTCOME

Stent thrombosis

Mortality risk ↑ 3.5x in *2/*2 carriers

PHARMACIST DECISION

Switch to Ticagrelor 90mg BID

CPIC Level A recommendation

MONITORING

Platelet reactivity units (PRU)<br><span style="font-size: 20px; color: #7DD3FC; margin-top: 8px; display: inline-block;">Target &lt;208 PRU</span>

3-month TEG/PlateletMapping

CPIC Guideline: Clopidogrel/CYP2C19 — Level A &nbsp;|&nbsp; PMID: 22547083

CLINICAL DECISION POINT — YOU DECIDE

CYP2C19 *2/*2 patient. Post-PCI. Day 30 readmission. What is YOUR recommendation?

Continue Clopidogrel + Increase dose to 150mg/day

Physician preference. Patient already on formulary drug.

Switch to Ticagrelor 90mg BID immediately

CPIC Level A. Bypasses CYP2C19. Direct P2Y12 inhibitor.

Add Aspirin 325mg and continue current regimen

Conservative approach. Avoid bleeding risk of switch.

RAISE YOUR HAND — A, B, or C?

30 seconds

Correct Answer: B — CPIC Grade A | Evidence Level: Strong

CLINICAL CASE 2 — ANTICOAGULATION

Warfarin's Genetic Complexity

CASE 02

<strong style="color: white;">67-year-old female.</strong> Atrial fibrillation. Started on Warfarin 5mg/day (standard initiation). Day 7: INR = 6.8. Major epistaxis. Hospitalized. Hematology consult. <span style="color: #FFB300;">Pharmacist reviews: No PGx testing done at initiation.</span>

GENOTYPE

VKORC1 -1639G&gt;A (AA genotype)<br>+ CYP2C9 *2/*3

Double genetic hit

PHENOTYPE

<strong style="color: white;">VKORC1:</strong> ↓↓ Vitamin K epoxide reductase expression (AA = most sensitive)<br><br><strong style="color: white;">CYP2C9 *2/*3:</strong> Impaired warfarin S-enantiomer metabolism

DRUG EXPOSURE

Warfarin clearance ↓ 60-70%

Standard dose = 3x effective dose in this patient

CLINICAL OUTCOME

Supratherapeutic INR 6.8

Major bleeding event. Preventable.

PHARMACIST DECISION

FDA-approved dosing algorithm: VKORC1 + CYP2C9 + CYP4F2 adjusted dose = <strong style="color: #00C896;">1.5mg/day</strong>

EU-PACT, COAG trial evidence

MONITORING

Daily INR first 5 days. Target 2.0-3.0. Genetic-guided stable dose in 2 weeks vs 6 weeks empiric.

The FDA updated Warfarin labeling in 2007 to include PGx. Why is this still not routine in your institution?

CPIC Warfarin Guideline | EU-PACT Trial | PMID: 24251363

CASE 03

CLINICAL CASE 3 — PSYCHIATRY

The Antidepressant Labyrinth

34-year-old female. Major Depressive Disorder. Failed 3 antidepressant trials over 18 months (Sertraline, Fluoxetine, Venlafaxine). Psychiatrist: 'Treatment-resistant depression.'

Pharmacist review: No CYP2D6 testing. Suspicion of pharmacokinetic resistance, not pharmacodynamic.

CYP2D6 *1/*2 xN

Gene duplication × 3. Ultra-Rapid Metabolizer.

Activity Score >2.0

Rapid elimination of all CYP2D6-substrate antidepressants.

Sertraline AUC ↓ 70%

Fluoxetine: active metabolite insufficient. Drug never reaches therapeutic window.

18 Months Misdiagnosed

Treated as treatment-resistant. Unnecessary polypharmacy. Patient stigmatized.

Switch to Mirtazapine

(not CYP2D6 substrate) OR Vortioxetine with dose escalation. CPIC: Avoid CYP2D6-dependent antidepressants in UM.

PHQ-9 Tracking

Monitor depression score at 4, 8, and 12 weeks. Plasma drug level confirmation if needed.

Is it pharmacodynamic or pharmacokinetic resistance? The pharmacist asks the question others don't.

PHARMACIST DECISION FRAMEWORK

CPIC SSRIs/SNRIs Guideline | PharmGKB CYP2D6 Annotations

CASE 04 — PEDIATRIC EMERGENCY

Codeine & The Silent Killer

3-year-old boy. Post-tonsillectomy.

Prescribed Codeine 1mg/kg q4-6h PRN for pain.

Hour 12:

Child found unresponsive. Respiratory rate: 4/min. Pupils: pinpoint. Naloxone administered. ICU admission.

Mother: "He only had 2 doses."

FDA BLACK BOX WARNING (2013)

Codeine contraindicated in pediatric post-tonsillectomy patients.

Ultra-Rapid CYP2D6 metabolizers at lethal risk.

GENOTYPE

PHENOTYPE

DRUG EXPOSURE

CLINICAL OUTCOME

PHARMACIST DECISION

MONITORING

<ul style="margin: 0; padding-left: 20px; color: #cbd5e1; display: flex; flex-direction: column; gap: 14px; font-size: 18px; line-height: 1.4;"><li>CYP2D6 *1/*2 xN</li><li style="color: white; font-weight: 600;"><span style="background: rgba(230,25,43,0.3); color: #ff8a98; padding: 3px 10px; border-radius: 6px; box-shadow: 0 0 10px rgba(230,25,43,0.2);">Ultra-Rapid Metabolizer</span></li><li style="color: #94a3b8; font-size: 16px;">Frequency: 1-2% European, 3-5% African, up to 16% Ethiopian populations</li></ul>

<ul style="margin: 0; padding-left: 20px; color: #cbd5e1; display: flex; flex-direction: column; gap: 14px; font-size: 18px; line-height: 1.4;"><li style="color: white; font-weight: 600;">Codeine &rarr; Morphine conversion:<br><span style="color: #ff4d5e; font-size: 21px; font-weight: 700; display: inline-block; margin-top: 6px;">300-400% of normal rate</span></li><li>Massive morphine generation within 2 hours</li></ul>

<ul style="margin: 0; padding-left: 20px; color: #cbd5e1; display: flex; flex-direction: column; gap: 14px; font-size: 18px; line-height: 1.4;"><li>Morphine plasma level:<br><span style="color: #ff4d5e; font-weight: 700; font-size: 21px; display: inline-block; margin-top: 6px;">5-10x expected</span></li><li style="color: white; font-weight: 600;">CNS opioid receptor saturation</li></ul>

<ul style="margin: 0; padding-left: 20px; color: #cbd5e1; display: flex; flex-direction: column; gap: 14px; font-size: 18px; line-height: 1.4;"><li style="color: #ff4d5e; font-weight: 800; font-size: 21px;">Fatal/near-fatal respiratory depression</li><li style="color: #94a3b8;">11 documented deaths reported to FDA (2004-2012)</li></ul>

<ul style="margin: 0; padding-left: 20px; color: #cbd5e1; display: flex; flex-direction: column; gap: 14px; font-size: 18px; line-height: 1.4;"><li style="color: white; font-weight: 600;">Contraindicate codeine in <span style="color: #ff4d5e;">all pediatric post-surgical patients</span></li><li>Substitute: Ibuprofen + Acetaminophen scheduled</li><li><span style="display:inline-block; border: 1px solid #00C896; color: #00C896; background: rgba(0,200,150,0.1); padding: 3px 8px; border-radius: 6px; font-size: 15px; font-weight: 800; margin-bottom: 6px; letter-spacing: 0.5px;">CPIC Level A</span><br>Avoid in UM phenotype</li></ul>

<ul style="margin: 0; padding-left: 20px; color: #cbd5e1; display: flex; flex-direction: column; gap: 14px; font-size: 18px; line-height: 1.4;"><li>If opioid required: Morphine with strict dose titration</li><li style="color: white; font-weight: 600; display: flex; align-items: center; gap: 10px; margin-left: -20px;"><div style="width: 10px; height: 10px; background: #00C896; border-radius: 50%; box-shadow: 0 0 10px #00C896; flex-shrink: 0;"></div> Continuous respiratory monitoring</li></ul>

FDA Drug Safety Communication 2013 | CPIC Codeine Guideline Level A | PMID: 22205192

Precision Medicine Framework

AI vs Pharmacist — Who Wins the PGx Decision?

AI Clinical Decision Support

Patient: CYP2C19 *2/*2 post-PCI

Recommendation: Consider alternative antiplatelet agent.

Suggested: Prasugrel or Ticagrelor.

Confidence: 87%

Source: CPIC Guidelines 2023

Technically correct. Clinically incomplete.

Clinical Pharmacist

✓ Confirms Ticagrelor — but ALSO checks:

Contraindication:

Prior stroke? (TIA history)

Drug interaction:

Concomitant strong CYP3A4 inhibitor?

Patient-specific:

Can afford $180/month vs $8 generic?

Cultural:

Will patient accept daily dual antiplatelet?

Monitoring plan:

PRU testing at 1 month

Educates patient on bleeding signs in Arabic

THE AUDIENCE CHALLENGE

What did the AI miss? Discuss with your neighbor — 60 seconds.

60 SEC

PART II: TARGETED DRUG DELIVERY

PGx Tells Us WHAT to Give.<br>Nano Tells Us HOW to Deliver It.

PGx identifies <strong style="color: white; font-weight: 700;">CYP2C19 *2/*2</strong>: Choose Ticagrelor, not Clopidogrel

Nanodelivery ensures Ticagrelor reaches <strong style="color: white; font-weight: 700;">P2Y12 receptor</strong> with controlled release

<strong style="color: white; font-weight: 700;">Ligand-targeted carriers:</strong> bypass hepatic first-pass for CYP-compromised patients

PGx-Guided Drug Selection &nbsp;+&nbsp; Nano-Optimized Delivery &nbsp;=&nbsp; Precision Pharmacotherapy

Genotype

Drug Selection via PGx

Delivery via Nanotechnology

Optimized Clinical Outcome

Targeted Drug Delivery Systems

Select delivery system based on patient's genotype-predicted metabolism profile.

Nanoemulsions

Oil-in-water droplets (50-200nm). Drug solubilized in lipid core. Enhanced oral bioavailability for poorly soluble drugs.

CYP2C9 PM patients: Cyclosporine nanoemulsion → predictable absorption despite reduced hepatic metabolism.

↑ Bioavailability

↓ Dose variance

Bypasses food effect

Ligand-Targeted

Surface-functionalized nanoparticles. Ligands: monoclonal antibodies, aptamers, folate. Active targeting to overexpressed receptors.

HER2+ breast cancer (ERBB2 variant): Trastuzumab-decorated nanoparticles deliver chemotherapy only to HER2+ cells.

↑ Selectivity

↓ Systemic toxicity

Genotype-matched targeting

Stimuli-Responsive

Release triggered by tumor microenvironment pH (6.5 vs 7.4), enzyme activity, or temperature. Smart release at site of action.

TPMT-deficient patients: pH-triggered 6-MP release in gut avoids systemic toxicity. CPIC guidance for thiopurines.

Site-specific

Enzyme-responsive

Reduces off-target effects

PGx + Nano: The Integrated Precision Pharmacotherapy Model

TOP LEVEL — PGx LAYER

BOTTOM LEVEL — NANO DELIVERY LAYER

Genotype Test

Metabolizer Phenotype

Drug Selection (CPIC)

Dose Calculation

Formulation Choice

Carrier Engineering

Targeting Strategy

Release Profile

OPTIMIZED DRUG EXPOSURE IN TARGET TISSUE

CYP2D6 UM: Increase dose + controlled-release nanocarrier to sustain therapeutic levels

CYP2C9 PM: Reduce dose + standard nanoemulsion for predictable absorption

HER2+ oncology: ERBB2-guided Trastuzumab + ligand-decorated nanoparticle

Clinical Pharmacist = The Integration Architect

⚡ RAPID-FIRE PGx CHALLENGE — ARE YOU READY?

5 HIGH-YIELD MCQs — 10 SECONDS EACH

A CYP2C19 *2/*2 patient on Omeprazole. What is expected?

A) Reduced acid suppression

B) Enhanced acid suppression

C) No change

D) Increased gastric bleeding

Q2: CYP2D6 UM + Codeine = ?

Q3: VKORC1 AA + Standard Warfarin = ?

Q4: Best delivery for CYP2C9 PM patient = ?

Q5: CPIC Level A for CYP2D6 + Codeine recommends = ?

10

Use your clinical reasoning. No notes. No phones. Just you and your training.

Traditional

Pharmacist Role

Dispensing

Drug Interaction Checker

Dose Calculator

Supporting Role

Reactive

Waits for orders

Clinical Pharmacist

in Precision Medicine

PGx Test Interpreter

Genotype-Guided Drug Selector

Therapeutic Drug Monitor

Nano-Delivery Consultant

Decision Authority

Proactive Intervener

Prevents harm before it happens

The clinical pharmacist who integrates PGx + nanotechnology is not a support role. They are the precision medicine architect.

The PGx Clinical Workflow

From Test to Monitoring

TEST

Genetic Testing

INTERPRET

Pharmacist Interpretation

DECIDE

Clinical Decision

MONITOR

Therapeutic Monitoring

Clinical Pharmacist leads Steps 2, 3, and 4.

REGIONAL LEADERSHIP

The MENA Advantage

Infrastructure gaps are opportunities for nations that move first

Infrastructure Gap = Opportunity

No legacy EHR to replace. Libya & MENA can build PGx-integrated systems from scratch. First-mover advantage in national PGx registry.

Genetic Uniqueness = Scientific Value

North African populations underrepresented in global PGx databases. CYP2D6 UM prevalence up to 3-5× higher than European. Unique founder alleles with global research value.

Academic Institutions as Launch Pads

Universities of Tripoli, Benghazi as PGx implementation centers. Train next-gen clinical pharmacists. Hospital-university partnerships.

FEASIBLE NOW — Pilot Model

Select cardiac/anticoagulation clinic

Partner with 1 lab for CYP2C19/VKORC1 genotyping

Assign clinical pharmacist as PGx interpreter

50 patients/month — track INR events & ADRs

Startup cost: ~$5,000 | ROI: 2 prevented hospitalizations = break even

Precision Medicine Symposium

Implementation Roadmap — Building a PGx-Ready Institution

Precision Medicine Implementation: From Zero to Clinical Practice

FOUNDATION

Month 1-3

Identify champion pharmacist + physician

Select 2-3 PGx genes (CYP2C19, VKORC1, CYP2D6)

Partner with genotyping laboratory

Select patient population (cardiology/anticoag)

$$ Low

PILOT

Month 4-9

Enroll 50-100 patients

Implement CPIC-based decision protocols

Track: ADR rates, hospitalizations, TTR for warfarin

Build PGx database — first MENA cohort

$$$ Moderate

SCALE

Month 10-18

Expand to oncology, psychiatry

Train 5+ pharmacists in PGx interpretation

Integrate into hospital EHR

Publish outcomes — MENA-first data

$$$$ Strategic investment

LEAD

Year 2+

National PGx registry

Regional MENA collaboration network

Clinical pharmacy PGx certification program

Pharmaceutical industry partnerships

Investment → Revenue

Barrier: Cost

Solution: Start with high-impact, low-cost genes (CYP2C19)

Barrier: Expertise

Solution: Online CPIC certification. PharmGKB free tools.

Barrier: Physician Buy-in

Solution: Show one prevented ADR. Data convinces.

Precision Medicine Framework

The Evidence Foundation

Every recommendation in this presentation is evidence-graded

Clinical Guidelines

Key Clinical Trials

Nanomedicine Resources

CPIC — Clinical Pharmacogenomics Implementation Consortium | cpicpgx.org | Level A-D evidence grading

PharmGKB — Pharmacogenomics Knowledgebase | pharmgkb.org | Gene-drug annotations

FDA PGx Biomarker Table | 300+ drug-gene pairs | Updated 2024

Dutch Pharmacogenetics Working Group (DPWG) | Complementary to CPIC

EU-PACT Trial (NEJM 2013) — Genotype-guided warfarin dosing | PMID: 24251363

TRITON-TIMI 38 — CYP2C19 & Clopidogrel outcomes | PMID: 19106084

GeneSight Trial — PGx in psychiatry reduces ADRs 30% | PMID: 31960068

COAG Trial — Warfarin PGx dosing | PMID: 24251363

Codeine Safety FDA Communication 2013 | PMID: 22205192

Torchilin VP. Nat Rev Drug Discov. 2014 — Nanocarrier drug delivery

Petros RA, DeSimone JM. Nat Rev Drug Discov. 2010 — Nanoparticle design

Peer D et al. Nature Nanotechnology 2007 — Cancer targeting

Duncan R. Nat Rev Cancer 2006 — Polymer therapeutics

AlSiraj Y et al. MENA PGx studies 2021 — Arab population CYP variants

All CPIC guidelines are freely accessible at cpicpgx.org | PharmGKB annotations at pharmgkb.org | FDA table: fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling

Leave This Room. Change One Thing Tomorrow.

5 Concrete Actions. No Exceptions.

01

Before prescribing a CYP2C19/2D6/2C9 substrate — ASK: Has this patient been genotyped?

START TODAY

02

Review your anticoagulation patients. Identify those on empiric warfarin without PGx testing.

THIS WEEK

03

Complete 1 free CPIC module at cpicpgx.org — Certify yourself in CYP2C19 or VKORC1

THIS MONTH

04

Find 1 physician ally. Show them one PGx case. Build the bridge.

THIS MONTH

05

Propose a 50-patient PGx pilot. Write the 1-page protocol tonight.

THIS QUARTER

"Precision medicine does not begin with a government program. It begins with a single pharmacist who decides: Not on my watch."

Precision Medicine Symposium

"The genome doesn't lie. The drug doesn't care about your protocol. Only the clinical pharmacist — armed with both — can bridge the gap between what the drug is supposed to do, and what it actually does in this patient, at this dose, right now."

— Precision Medicine Principle

Genotype → Phenotype → Drug Exposure → Clinical Outcome → Decision → Monitoring

[Email]

[LinkedIn]

Clinical Pharmacist | Precision Medicine | PGx | Targeted Delivery